Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis

Company Overview

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria. The company also markets additional specialty medicines through licensing, partnerships and acquisitions.

The company’s roots extend to Swedish pharmaceutical operations established in the 1930s, while the modern Sobi organization was formed through the combination of Swedish Orphan and Biovitrum. Headquartered in Stockholm, Sobi serves patients and healthcare providers across Europe, North America and other international markets through its commercial, research and development operations and relationships with external partners.

Key Stats

• Today's Range: $42.90 to $42.90
• 50-Day Range: $42.90 to $49.03
• 52-Week Range: $33.30 to $49.03
• Volume: N/A
• Average Volume: 22 shs
• Market Capitalization: $15.27 billion
• P/E Ratio: 95.34
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Swedish Orphan Biovitrum Stock Analysis - MarketRank™

Swedish Orphan Biovitrum scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Swedish Orphan Biovitrum has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Swedish Orphan Biovitrum has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 73.30%

Earnings Growth

Earnings for Swedish Orphan Biovitrum are expected to grow by 73.30% in the coming year, from $1.91 to $3.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Swedish Orphan Biovitrum is 95.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.83.

Price to Earnings Ratio vs. Sector

The P/E ratio of Swedish Orphan Biovitrum is 95.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.58.

Price to Book Value per Share Ratio

Swedish Orphan Biovitrum has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Swedish Orphan Biovitrum has been sold short.

Short Interest Ratio / Days to Cover

Swedish Orphan Biovitrum has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Swedish Orphan Biovitrum has recently decreased by 43.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Swedish Orphan Biovitrum does not currently pay a dividend.

Dividend Growth

Swedish Orphan Biovitrum does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.44

News Sentiment

Swedish Orphan Biovitrum has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Swedish Orphan Biovitrum this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Swedish Orphan Biovitrum insiders have not sold or bought any company stock.

Percentage Held by Institutions

Swedish Orphan Biovitrum has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 10/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BIOVF
• CIK: N/A
• Web: www.sobi.com
• Phone: (468) 697-2000
• Fax: N/A
• Employees: 1,900
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): $0.45
• Trailing P/E Ratio: 95.34
• Forward P/E Ratio: 22.46
• P/E Growth: N/A
• Net Income: $48.85 million
• Net Margins: 4.74%
• Pretax Margin: 4.68%
• Return on Equity: 17.72%
• Return on Assets: 9.27%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 0.88
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: $2.89 billion
• Price / Sales: 5.29
• Cash Flow: $4.57 per share
• Price / Cash Flow: 9.38
• Book Value: $10.83 per share
• Price / Book: 3.96

Miscellaneous

• Outstanding Shares: 356,000,000
• Free Float: N/A
• Market Cap: $15.27 billion
• Optionable: Not Optionable
• Beta: 0.33